Cytokinetics is a pioneering late-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel muscle-directed therapies. With a deep understanding of muscle biology and the mechanics of muscle performance, Cytokinetics focuses on creating first-in-class and best-in-class treatments for diseases characterized by impaired muscle function, such as heart failure, hypertrophic cardiomyopathy (HCM), and amyotrophic lateral sclerosis (ALS). Their innovative approach targets muscle contractility to improve the health span of patients with debilitating conditions.
Serves as the central hub for research and development, corporate operations, clinical development, and strategic decision-making for its global activities.
State-of-the-art laboratory facilities equipped for advanced muscle biology research, collaborative office spaces designed to foster innovation, and proximity to a rich ecosystem of biotech peers and academic institutions.
Characterized by a science-driven, patient-focused environment that encourages collaboration, innovation, scientific rigor, and a collective commitment to addressing unmet medical needs in severe diseases.
The South San Francisco location places Cytokinetics at the epicenter of biopharmaceutical innovation, facilitating access to top-tier talent, leading research institutions, and key industry partners, crucial for its R&D and commercial aspirations.
While headquartered in the U.S., Cytokinetics maintains a global outlook, primarily through its extensive clinical trial operations conducted across North America, Europe, Asia, and other regions. The company is actively preparing for potential global commercialization of its late-stage drug candidates and engages with international regulatory bodies, research collaborators, and patient advocacy groups worldwide. Its strategy includes building infrastructure to support potential international product launches and market access.
350 Oyster Point Boulevard
South San Francisco
CA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cytokinetics' leadership includes:
Cytokinetics has been backed by several prominent investors over the years, including:
Over the past 12 months, Cytokinetics has significantly bolstered its executive leadership, particularly in commercial and people operations, gearing up for potential product launches and organizational growth. Key appointments include a new Chief Commercial Officer, an EVP of Commercial Strategy & Operations, and an EVP, Chief People and Culture Officer. No high-profile executive departures were publicly announced during this period.
Discover the tools Cytokinetics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Cytokinetics, Inc. most commonly utilizes the email format combining the first initial of an employee's name with their full last name, followed by '@cytokinetics.com'. This is a standard professional email structure within the biopharmaceutical industry.
flast@cytokinetics.com
Format
rblum@cytokinetics.com
Example
90%
Success rate
Cytokinetics Investor Relations • May 7, 2024
Cytokinetics reported its financial results for the first quarter of 2024, providing updates on its cash position, R&D expenditures, and progress on its pipeline, particularly aficamten....more
Cytokinetics Investor Relations • February 13, 2024
The U.S. Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) target action date by three months for the New Drug Application (NDA) for aficamten, for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM), to November 30, 2024....more
Cytokinetics Investor Relations • December 27, 2023
Cytokinetics announced that SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten, met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements in exercise capacity for patients with oHCM....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cytokinetics, are just a search away.